Back to Search Start Over

Virtual Molecular and Precision Medicine Clinic to Improve Access to Clinical Trials for Patients With Metastatic Breast Cancer: An Academic/Community Collaboration.

Authors :
Spring, Laura M.
Mortensen, Lindsey
Abraham, Elizabeth
Keenan, Jennifer
Medford, Arielle
Ma, Annie
Padden, Sarah
Denault, Elyssa
Ryan, Lianne
Iafrate, A. John
Lennerz, Jochen
Hochberg, Ephraim
Wander, Seth A.
Moy, Beverly
Isakoff, Steven J.
Juric, Dejan
Brennan, Kimberly A.
Smith, Deborah E.
Civiello, Barbara
Mulvey, Therese
Source :
JCO Oncology Practice; Jan2024, Vol. 20 Issue 1, p69-76, 10p
Publication Year :
2024

Abstract

PURPOSE There is a demand for improved care delivery surrounding genomic testing and clinical trial enrollment among patients with metastatic breast cancer (MBC). We sought to improve the current process via real-time informal consultation and prescreening assessment for patients with MBC treated by community and academic medical oncologists by implementing a virtual molecular and precision medicine (vMAP) clinic. METHODS The vMAP program used a virtual referral system directed to a multidisciplinary team with precision medicine expertise. Providers contacted vMAP regarding patients with MBC, and on receipt of referral, the vMAP team engaged in discussion to identify if further diagnostics were needed (including genomic testing) and to identify potential clinical trials or standard treatment options. Recommendations were then sent to the referring provider within 72 hours. Pre-/postsurveys were issued to network physicians to assess for barriers, clinical trial access, and vMAP referral experience. Program implementation was evaluated with the Squire 2.0 reporting guidelines for quality improvement in health care as a framework. RESULTS Eighty-one cases from 22 providers were referred to vMAP over a 26-month period. The average response time to the referring provider with a finalized recommendation was 1.90 ± 1.82 days. A total of 86.4% of cases had clinical trial options on vMAP prescreen, with 40.7% initiating formal screening assessments and 27 patients (33.3%) ultimately enrolling on trials. On resurvey, 92% of survey responses across community oncology referring providers said that they were very likely to use vMAP again. CONCLUSION In the initial 2-year period, vMAP demonstrated an efficient means to offer real-time interpretation of genomic testing and identification of clinical trials for patients with MBC, with effective clinical trial enrollment and high rates of referring provider satisfaction. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
26881527
Volume :
20
Issue :
1
Database :
Complementary Index
Journal :
JCO Oncology Practice
Publication Type :
Academic Journal
Accession number :
174771936
Full Text :
https://doi.org/10.1200/OP.23.00193